The European Prevention of Alzheimer's Dementia Consortium (EPAD), a project co-funded by the Innovative Medicines Initiative (IMI) and the European Federation of Pharmaceutical Industries and Associations (EFPIA), announced the official launch of www.ep-ad.org on 21 September. The EPAD website is devoted to inform different audiences including the scientific community, companies, people with dementia, families and carers, Alzheimer associations and the general public, about the project's existence, its progress and its achievements.
"21 September 2015 was not chosen randomly since it is the date of World Alzheimer's Day." says Jean Georges, Executive Director of Alzheimer Europe and EPAD communication co-lead. "EPAD wants to contribute to raising awareness on Alzheimer's disease and more specifically on the importance of the prevention of Alzheimer's dementia.
"EPAD does not only want to innovate in clinical trial design: we want to make a real difference in the communication with research participants. Together with EPAD's ethics working group, we are currently searching for the most meaningful and comprehensive methods and mechanisms for feedback from all the volunteers who will be involved in EPAD and who will help us gain a better understanding of how Alzheimer's disease progresses and how it may be prevented."